Search
forLearn
5 / 801 resultslearn ACETYL TETRAPEPTIDE-2
learn ppg-26-buteth-26
learn APISCALP™
learn AMINOPROPANEDIOL ESTERS
Research
5 / 237 resultsresearch 567 Acute generalized exanthematous pustulosis (AGEP) induced by plaquenil
Plaquenil can cause a severe skin reaction called AGEP, requiring prompt diagnosis and treatment.
research Age dependence of the cardiac lesions induced by minoxidil in the rat
Older rats more affected by minoxidil's cardiotoxic effects than younger rats.
research Age-Related Differences for Male-to-Female Transgender Patients Undergoing Gender-Affirming Surgery
Younger transgender women have surgery earlier, are mostly attracted to men, and show more preoperative depression that improves after surgery compared to older transgender women.
research Age-related changes in the hair follicle and hair shaft in women in the parietal region
As women age, hair follicles decrease in number and hair width tends to reduce.
research A clinical investigation of early‐onset alopecia areata in children: Onset earlier than 4 years of age might have a better short‐term prognosis
Children with alopecia areata before age 4 may have better short-term hair regrowth.
Community Join
5 / 1000+ resultscommunity GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community GT20029 Anageninc Market Availability
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
community ASATONA AG and "Asatex"
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.